The Stoned Ape Theory: Pseudoscience or Psychedelic Origin of Modern Man?
Did early humans accelerate evolution by tripping balls on psychedelic mushrooms? One psychonaut ethnobiologist says: absolutely.
psilocybin
Scientists Begin Exploring Therapeutic Potential of Psilocybin Mushrooms Native to Australia
“Australian native ‘magic mushrooms’ may have evolved different methods for psilocybin production and offer adaptations that are preferential for use in clinical treatments,” explains University of Queensland mycologist Dr. Alistair McTaggart.
Psychedelic Business Spotlight: August 27, 2021
Delic establishes medical board to oversee psychedelic treatment protocols, cool new delivery systems investigated for psychedelics, and VR meets psychedelic therapies, finally.
MindSet Pharma Says Its Psilocybin Formula Is the ‘Perfect Microdosing Drug’
“The potential market for microdosing could be absolutely enormous because it is easier, more convenient, and more familiar,” says Mindset Pharma CEO James Lanthier.
Kacey Musgraves Says ‘Life-Changing’ Psilocybin Trip Transformed Her Trauma Into New Album
This isn’t the first time the hit songwriter has turned to psychedelics for therapy, either.
TRIPP Acquires PsyAssist to Empower Psychedelic Therapies with Virtual Reality
Clinicians are currently using TRIPP to help immerse patients into alternative realities and to support patients’ wellbeing before, during, and after ketamine-assisted therapy.
Decriminalize Nature Co-Founder Carlos Plazola Wants to Free Entheogens Everywhere
Since May 2019, nine cities and the state of Oregon have decriminalized psychedelics. Carlos Plazola has had his hand in nearly all of them.
Psychedelic Business Spotlight: August 20, 2021
This week in psychedelic business news: More psychedelic clinical trials are green-lighted, new partnerships inked, and Beckley Psytech successfully completes upsized Series B financing.
Why PsyBio Is Using Biosynthetic Psilocybin, Not Mushrooms, to Build Better Therapeutics
“A mushroom is not a pharmaceutical product,” CEO Evan Levine stresses, and explains why his company’s method of biologically engineering psilocybin is “cheaper, faster, greener.”
Canada Green Lights Country’s Third Clinical Psilocybin Study
The trial will build on Diamond Therapeutic’s previous animal research that demonstrated how non-hallucinogenic doses of psilocybin hold the potential to treat psychiatric disorders, including anxiety and depression.
End of content
End of content